Barclays’s Inhibikase Therapeutics IKT Stock Holding History
Bought
Maintained
Sold
Other funds holding IKT
SL
Barclays's IKT Position: Q3 2026 in Review
Barclays increased its Inhibikase Therapeutics (IKT) stake by 244% in Q3 2026, buying an estimated $109K and bringing the position to 67,839 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #4170.
Barclays first reported a position in IKT in Q2 2023 and has held it in 9 quarters since. The position peaked at $273K in Q4 2024. 110 funds tracked by Wall St. Rank hold IKT as of Q3 2026.
- Barclays held 67,839 shares of Inhibikase Therapeutics worth $139K as of Q3 2026.
- Barclays bought 48,114 Inhibikase Therapeutics shares in Q3 2026, an estimated $109K.
- Inhibikase Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4170 holding.
- Barclays first reported a position in Inhibikase Therapeutics in Q2 2023 and has held it in 9 quarters since.
- Barclays's Inhibikase Therapeutics position peaked at $273K in Q4 2024.
- 110 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.